- The IPO hangover $EDIT $BGNE $PTI $AVXS
- Clinical trial trouble for CTI, Biocryst and Incyte $CTIC $BCRX $INCY
- Luminaries talk drug prices at #BIOCEO16 (special thanks to @ldtimmerman for the live coverage)
- Celltrion's favorable FDA Advisory Committee meeting for its biosimilar Humira $ABBV
- Bluebird bio is a poster child for sentiment shifts $BLUE
- Catalyst slammed with FDA "refuse to file" letter $CPRX
- Data from Flexion, Regulus and Aerie met with questions $FLXN $RGLS $AERI
- As seen on the stream (the best of everything else!)
Continue to the Biotech Tweets of the Week (February 8-19, 2016)